New fill-finish plant strengthens nation’s reputation as an APAC biomedical hub.
Thermo Fisher Scientific, a contract development and manufacturing organization (CDMO),has opened a new sterile drug facility in Singapore that will better enable customers to deliver new medicines and vaccines in the Asia-Pacific (APAC) market. The new facility also represents milestone and investment in pandemic preparedness for Singapore, who serves as a biomedical hub in the region.
Established with assistance from the Singapore Economic Development Board (EDB), in alignment with the government’s investment in preparedness for future health emergencies, the current good manufacturing practices (cGMP) facility will provide rapid vaccine fill-finish capabilities, along with the CDMO’s end-to-end pharma development and manufacturing services.
“We are committed to serving as a reliable partner to the Asia-Pacific region and the world,” says Michel Lagarde, executive vice president and COO at Thermo Fisher Scientific. “This new site is an important extension of Thermo Fisher’s robust sterile fill-finish global network. With this expansion, we are strategically prepared, more than ever, to respond to our customers’ needs by supporting the accelerated delivery of critical vaccines and medicines to patients.”